Novo Nordisk announced the launch of a next generation of FlexPen® at the European Association for the Study of Diabetes (EASD) Annual Meeting. The new insulin injection device builds upon the high standards set by the current version of FlexPen®, with new features providing improved safety, convenience and ease of use for people with diabetes. FlexPen® is already the most widely used prefilled insulin device in the world(1), benefiting millions of people with diabetes worldwide.
The details can be read here.
No comments:
Post a Comment